Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FOLD 
Amicus Therapeutics Inc (FOLD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: FOLD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $16.09
1 Year Target Price $16.09
| 8 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.6% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.35B USD | Price to earnings Ratio - | 1Y Target Price 16.09 |
Price to earnings Ratio - | 1Y Target Price 16.09 | ||
Volume (30-day avg) 12 | Beta 0.53 | 52 Weeks Range 5.51 - 12.65 | Updated Date 08/24/2025 |
52 Weeks Range 5.51 - 12.65 | Updated Date 08/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -6.67% | Operating Margin (TTM) -5.02% |
Management Effectiveness
Return on Assets (TTM) 2% | Return on Equity (TTM) -22.62% |
Valuation
Trailing PE - | Forward PE 285.71 | Enterprise Value 2558018636 | Price to Sales(TTM) 4.11 |
Enterprise Value 2558018636 | Price to Sales(TTM) 4.11 | ||
Enterprise Value to Revenue 4.48 | Enterprise Value to EBITDA 77.37 | Shares Outstanding 308239008 | Shares Floating 288206897 |
Shares Outstanding 308239008 | Shares Floating 288206897 | ||
Percent Insiders 0.72 | Percent Institutions 104.75 |
Upturn AI SWOT
Amicus Therapeutics Inc
Company Overview
History and Background
Amicus Therapeutics Inc. was founded in 2002. The company focuses on discovering, developing, and commercializing novel medicines for rare diseases. Significant milestones include the approval of Galafold for Fabry disease and ongoing development of gene therapy programs.
Core Business Areas
- Rare Disease Therapeutics: Focuses on developing and commercializing therapies for rare genetic diseases, with a primary emphasis on lysosomal storage disorders (LSDs).
- Gene Therapy: Developing gene therapies for various genetic disorders. Researching AAV vector technology for targeted delivery.
Leadership and Structure
The leadership team includes John F. Crowley (Chairman and CEO). The organizational structure includes research and development, commercial operations, and manufacturing divisions.
Top Products and Market Share
Key Offerings
- Galafold (Migalastat): An oral chaperone therapy approved for certain amenable mutations of Fabry disease. While precise market share data fluctuates, Galafold is a key player in the Fabry disease market. The Fabry disease market is competitive and the main competitors include Sanofi's Fabrazyme and Takeda's Replagal. Revenue: See financial performance section
- Pipeline Gene Therapy Products: Gene therapy programs for Pompe disease, Batten disease, and other genetic conditions. These are in the development stage. Competitors include companies developing gene therapies for similar diseases, like Sarepta Therapeutics (SRPT).
Market Dynamics
Industry Overview
The rare disease therapeutics market is growing due to increased awareness, orphan drug designations, and advancements in genetic research and gene therapy. High unmet needs drive innovation and investment.
Positioning
Amicus Therapeutics Inc. is positioned as a leader in developing therapies for rare diseases, particularly lysosomal storage disorders, leveraging its expertise in small molecule chaperones and gene therapy.
Total Addressable Market (TAM)
The total addressable market for rare disease therapeutics is estimated to be over $200 billion. Amicus is positioned to capture a significant share of this market through its established products like Galafold and its pipeline of gene therapies.
Upturn SWOT Analysis
Strengths
- Approved product (Galafold) with established market presence
- Strong pipeline of gene therapy programs
- Experienced management team
- Focus on rare diseases with high unmet needs
- Strong partnerships and collaborations
Weaknesses
- Reliance on single approved product for revenue
- High R&D expenses
- Regulatory hurdles for gene therapy products
- Competition from established pharmaceutical companies
Opportunities
- Expansion of Galafold to new markets and indications
- Approval and commercialization of gene therapy products
- Strategic acquisitions and collaborations
- Advancements in gene therapy technology
Threats
- Regulatory setbacks
- Clinical trial failures
- Competition from novel therapies
- Patent expirations
- Pricing pressures
Competitors and Market Share
Key Competitors
- SNY
- TAK
Competitive Landscape
Amicus benefits from Galafold being the only oral therapy for amenable mutations of Fabry disease and has a growing gene therapy pipeline. However, faces competition from large pharmaceutical companies like Sanofi and Takeda with more resources and established infrastructure.
Major Acquisitions
Callidus Biopharma
- Year: 2013
- Acquisition Price (USD millions): 130
- Strategic Rationale: Acquisition of Callidus expanded Amicus's portfolio and pipeline in lysosomal storage disorders.
Growth Trajectory and Initiatives
Historical Growth: Amicus has experienced strong revenue growth driven by Galafold sales. R&D expenses remain high as the company invests in its gene therapy pipeline.
Future Projections: Analysts project continued revenue growth driven by Galafold and potential approvals of gene therapy products. Profitability is expected to improve as revenue scales.
Recent Initiatives: Recent initiatives include expanding the Galafold label, advancing gene therapy programs through clinical trials, and strategic partnerships.
Summary
Amicus Therapeutics Inc. is a biopharmaceutical company focused on rare diseases. Its primary revenue driver is Galafold, approved for Fabry disease. The company is investing heavily in gene therapy programs, which hold significant growth potential. However, it faces competition, regulatory hurdles, and substantial R&D expenses. Improving cash flows and growing market share are key to its long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Amicus Therapeutics Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data are estimates and may vary. Financial data are subject to change. Conduct your own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amicus Therapeutics Inc
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2007-05-31 | CEO, President & Director Mr. Bradley L. Campbell M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 499 | Website https://amicusrx.com |
Full time employees 499 | Website https://amicusrx.com | ||
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.